{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:59:01Z","timestamp":1793271541611,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"European League Against Rheumatism","doi-asserted-by":"publisher","award":["QoC016"],"award-info":[{"award-number":["QoC016"]}],"id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1136\/ard-2024-225531","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T13:23:17Z","timestamp":1710768197000},"page":"706-719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":397,"title":["EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update"],"prefix":"10.1016","volume":"83","author":[{"given":"Laure","family":"Gossec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo J O","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Bertheussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente Appel","family":"Esbensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andra","family":"Balanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter V","family":"Balint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Claudepierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Iagnocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Erik","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Lories","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Queiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Wagenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J W","family":"Shoop-Worrall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip E","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"van der Helm-van Mil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alen","family":"Zabotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2024-225531_bib1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib2","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.semarthrit.2020.01.012","article-title":"Remission in psoriatic arthritis: definition and predictors","volume":"50","author":"Alharbi","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2024-225531_bib3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PSA: lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003339","article-title":"Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise - a review","volume":"9","author":"Lubrano","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-225531_bib5","first-page":"1","article-title":"Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis","author":"Kerschbaumer","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225531_bib9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of Psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and Psoriatic arthritis (GRAPPA): updated treatment recommendations for Psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105469","article-title":"The updated GRAPPA and EULAR recommendations for the management of Psoriatic arthritis: similarities and differences","volume":"90","author":"Coates","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2024-225531_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"American college of rheumatology\/national psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib14","author":"Chalmers"},{"key":"10.1136\/ard-2024-225531_bib15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League against rheumatism (EULAR) recommendations for the management of Psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1136\/ard-2024-225531_bib17","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1093\/rheumatology\/keac210","article-title":"All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study","volume":"61","author":"Kerola","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225531_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101689","article-title":"Cardiovascular disease and depression in Psoriatic arthritis: multidimensional Comorbidities requiring Multidisciplinary management","volume":"35","author":"So","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105344","article-title":"French society for rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis","volume":"89","author":"Wendling","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2024-225531_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000585","article-title":"Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study","volume":"5","author":"Smolen","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-225531_bib21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/1744666X.2020.1740593","article-title":"Metabolic syndrome and psoriatic arthritis: considerations for the clinician","volume":"16","author":"Caso","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1136\/ard-2024-225531_bib22","article-title":"Cardiovascular risk, and therapeutic management in obesity and Psoriatic arthritis","volume":"11","author":"Porta","year":"2020","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-225531_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003157","article-title":"Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study","volume":"9","author":"Leung","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-225531_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105399","article-title":"Assessing central sensitization with quantitative sensory testing in inflammatory rheumatic diseases: a systematic review","volume":"89","author":"Trouvin","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2024-225531_bib25","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1093\/rheumatology\/keaa780","article-title":"Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study","volume":"60","author":"Ballegaard","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2024-225531_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib27","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225531_bib28","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.semarthrit.2017.10.021","article-title":"Considerations for the definition of remission criteria in psoriatic arthritis","volume":"47","author":"Mease","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2024-225531_bib29","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/rheumatology\/keaa030","article-title":"Remission and low disease activity in Psoriatic arthritis publications: a systematic literature review with meta-analysis","volume":"59","author":"Hag\u00e8ge","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225531_bib30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/annrheumdis-2020-216999","article-title":"Use of multidimensional composite scores in rheumatology: parsimony versus subtlety","volume":"80","author":"Landew\u00e9","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib32","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1093\/rheumatology\/keac129","article-title":"Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review","volume":"61","author":"Vincken","year":"2022","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2024-225531_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib34","unstructured":"Zabotti A, Fagni F, Gossec L, et al. n.d. Subclinical psoriatic arthritis and new onset psoriatic arthritis in subjects transitioning from psoriasis: an analysis of 2 longitudinal cohorts. In Review, RMD Open"},{"key":"10.1136\/ard-2024-225531_bib35","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1093\/rheumatology\/keab233","article-title":"The burden of psoriatic arthritis in the biologics era: data from the Belgian epidemiological psoriatic arthritis study","volume":"60","author":"de Vlam","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2024-225531_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101670","article-title":"Clinical features of psoriatic arthritis","volume":"35","author":"Kishimoto","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib37","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2019-216500","article-title":"GO-DACT: a phase 3B randomised, double-blind, placebo-controlled trial of golimumab plus methotrexate (MTX) versus placebo plus MTX in improving dactylitis in MTX-naive patients with psoriatic arthritis","volume":"79","author":"Vieira-Sousa","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib38","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2665-9913(22)00028-5","article-title":"Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PSA): a double-blind, placebo-controlled, randomised, trial","volume":"4","author":"Mulder","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib39","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2665-9913(22)00008-X","article-title":"Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study","volume":"4","author":"Coates","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying Antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002883","article-title":"Methotrexate treatment in early Psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study","volume":"9","author":"Lindstr\u00f6m","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-225531_bib42","article-title":"Methotrexate for psoriatic arthritis","volume":"1","author":"Wilsdon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ard-2024-225531_bib43","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221092376","article-title":"Is there still a place for methotrexate in severe psoriatic arthritis","volume":"14","author":"Felten","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2024-225531_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/RHU.0000000000000810","article-title":"Folate supplementation for methotrexate therapy in patients with rheumatoid arthritis: a systematic review","volume":"25","author":"Liu","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of Ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib47","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3B trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225531_bib48","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/annrheumdis-2021-221640","article-title":"Persistence and effectiveness of the IL-12\/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world Psabio study","volume":"81","author":"Gossec","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib49","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002074","article-title":"Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-225531_bib51","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ard-2024-225531_bib52","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ard-2024-225531_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225531_bib54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-A inhibitors: a randomised","volume":"401","author":"Merola","year":"2023","journal-title":"The Lancet"},{"key":"10.1136\/ard-2024-225531_bib55","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological Dmards based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225531_bib56","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib57","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41584-022-00810-7","article-title":"Sex- and gender-related differences in Psoriatic arthritis","volume":"18","author":"Tarannum","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib58","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/acr.24090","article-title":"Determinants of patient-reported psoriatic arthritis impact of disease: an analysis of the association with sex in 458 patients from fourteen countries","volume":"72","author":"Orbai","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2024-225531_bib59","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/annrheumdis-2021-220097","article-title":"Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib60","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/keu415","article-title":"Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PSA: a systematic review of the literature","volume":"54","author":"Behrens","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225531_bib61","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2665-9913(22)00329-0","article-title":"Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, Multicentre, placebo-controlled, phase 3B, non-inferiority trial","volume":"5","author":"Koehm","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib62","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","article-title":"The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study","volume":"73","author":"Fagerli","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib63","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225531_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-225531_bib65","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib66","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib67","article-title":"16-week results from FOREMOST, a placebo-controlled study involving oligoarticular psoriatic arthritis treated with apremilast","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib68","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib69","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/rheumatology\/kex079","article-title":"The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia","volume":"57","author":"Marchesoni","year":"2018","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2024-225531_bib70","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"80","author":"Baraliakos","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225531_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001149","article-title":"Effects of ustekinumab on spondylitis-associated endpoints in Tnfi-na\u00efve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials","volume":"6","author":"Helliwell","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-225531_bib72","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib73","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2024-225531_bib74","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/rheumatology\/keab622","article-title":"Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study","volume":"61","author":"Ogdie","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225531_bib75","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225531_bib76","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225531_bib77","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.20413","article-title":"Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study","volume":"185","author":"Gottlieb","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2024-225531_bib78","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of Ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2024-225531_bib79","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1136\/ard-2024-225531_bib80","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/rheumatology\/keaa062","article-title":"Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis","volume":"59","author":"Pittam","year":"2020","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2024-225531_bib81","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225531_bib82","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225531_bib83","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225531_bib84","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225531_bib85","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225531_bib86","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1093\/rheumatology\/keab819","article-title":"New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study","volume":"61","author":"Letarouilly","year":"2022","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2024-225531_bib87","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1080\/03007995.2019.1620713","article-title":"Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with Interleukin-17A or phosphodiesterase 4 inhibitors","volume":"35","author":"Emond","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1136\/ard-2024-225531_bib88","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/apt.15397","article-title":"Systematic review with meta-analysis: risk of new onset IBD with the use of anti-Interleukin-17 agents","volume":"50","author":"Yamada","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1136\/ard-2024-225531_bib89","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40265-018-0994-3","article-title":"Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity","volume":"78","author":"Ye","year":"2018","journal-title":"Drugs"},{"key":"10.1136\/ard-2024-225531_bib90","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/art.41716","article-title":"Withdrawing Ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study","volume":"73","author":"Coates","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib91","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/03009742.2022.2028364","article-title":"Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial","volume":"52","author":"Ruwaard","year":"2023","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1136\/ard-2024-225531_bib92","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2665-9913(20)30339-8","article-title":"Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL balance","volume":"3","author":"Nash","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-225531_bib93","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/ard-2022-222779","article-title":"Understanding sex-related differences in Healthcare utilisation among patients with inflammatory arthritis: a population-based study","volume":"82","author":"Tarannum","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724001274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724001274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2024-225531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:01:23Z","timestamp":1779249683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724001274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0003496724001274"],"URL":"https:\/\/doi.org\/10.1136\/ard-2024-225531","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2024-225531","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 European Alliance of Associations for Rheumatology, EULAR 2024. Re-use permitted under CC BY-NC-ND. No commercial re-use. No derivatives. See rights and permissions. Published by Elsevier Inc. on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}